Collegium Pharmaceutical, Inc. (COLL)

USD 30.02

(-2.85%)

Market Cap (In USD)

968.15 Million

Revenue (In USD)

566.76 Million

Net Income (In USD)

48.15 Million

Avg. Volume

419.17 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
28.97-42.287
PE
-
EPS
-
Beta Value
0.949
ISIN
US19459J1043
CUSIP
19459J104
CIK
1267565
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.
Employee Count
-
Website
https://www.collegiumpharma.com
Ipo Date
2015-05-07
Details
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.